A Phase 1 safety, tolerability, and pharmacokinetic study of single-and multiple-ascending doses of
muvalaplin (LY3473329) 30 mg-800 mg in healthy volunteers
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
